Insights

Innovative Therapeutics Focus Zevra Therapeutics specializes in developing treatments for rare diseases, addressing significant unmet medical needs which presents opportunities to collaborate on specialized product development, clinical trials, and regulatory support.

Growing Clinical Pipeline The recent launch of Niemann-Pick Disease Type C and ongoing development of therapies for vEDS indicate an expanding portfolio, offering potential for partnership in research, manufacturing, and commercialization of novel therapies.

Strategic Event Participation Active participation in industry conferences and innovation events signals openness to networking and strategic alliances, making it easier to establish connections for distribution, research collaborations, or co-development projects.

Financial Capacity With revenue between 25M and 50M and funding of 60M, Zevra has the financial resources to support partnerships, clinical expansion, and joint ventures in targeted rare disease markets.

Focus on Cutting-Edge Technology Utilizing advanced tech stacks such as CIM Technologies and analytics tools, Zevra values innovative solutions, presenting opportunities to partner in digital health, data management, and technology-driven research initiatives.

Similar companies to Zevra Therapeutics

Zevra Therapeutics Tech Stack

Zevra Therapeutics uses 8 technology products and services including CIM Technologies, NetSuite, BugHerd, and more. Explore Zevra Therapeutics's tech stack below.

  • CIM Technologies
    Cad & Graphics
  • NetSuite
    E-commerce
  • BugHerd
    Issue Trackers
  • Glassdoor
    Online Review Management
  • HSTS
    Security
  • Google Tag Manager
    Tag Management
  • Adobe Creative Suite
    Visualisation Software
  • Google Analytics
    Web Analytics

Media & News

Zevra Therapeutics's Email Address Formats

Zevra Therapeutics uses at least 2 format(s):
Zevra Therapeutics Email FormatsExamplePercentage
FLast@kempharm.comJDoe@kempharm.com
99%
FirLast@kempharm.comJohDoe@kempharm.com
1%
FLast@zevra.comJDoe@zevra.com
100%

Frequently Asked Questions

What is Zevra Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Zevra Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Zevra Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Zevra Therapeutics's official website is zevra.com and has social profiles on LinkedInCrunchbase.

What is Zevra Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Zevra Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Zevra Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, Zevra Therapeutics has approximately 67 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Chief Executive Officer: N. M.Chief Executive Officer: T. W.Chief Medical Officer: A. Q.. Explore Zevra Therapeutics's employee directory with LeadIQ.

What industry does Zevra Therapeutics belong to?

Minus sign iconPlus sign icon
Zevra Therapeutics operates in the Biotechnology Research industry.

What technology does Zevra Therapeutics use?

Minus sign iconPlus sign icon
Zevra Therapeutics's tech stack includes CIM TechnologiesNetSuiteBugHerdGlassdoorHSTSGoogle Tag ManagerAdobe Creative SuiteGoogle Analytics.

What is Zevra Therapeutics's email format?

Minus sign iconPlus sign icon
Zevra Therapeutics's email format typically follows the pattern of FLast@kempharm.com. Find more Zevra Therapeutics email formats with LeadIQ.

How much funding has Zevra Therapeutics raised to date?

Minus sign iconPlus sign icon
As of December 2025, Zevra Therapeutics has raised $60M in funding. The last funding round occurred on Aug 08, 2024 for $60M.

When was Zevra Therapeutics founded?

Minus sign iconPlus sign icon
Zevra Therapeutics was founded in 2006.

Zevra Therapeutics

Biotechnology ResearchFlorida, United States51-200 Employees

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies.

With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients.

Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.

Section iconCompany Overview

Phone number
Website
zevra.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2006
Employees
51-200

Section iconFunding & Financials

  • $60M

    Zevra Therapeutics has raised a total of $60M of funding over 9 rounds. Their latest funding round was raised on Aug 08, 2024 in the amount of $60M.

  • $25M$50M

    Zevra Therapeutics's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $60M

    Zevra Therapeutics has raised a total of $60M of funding over 9 rounds. Their latest funding round was raised on Aug 08, 2024 in the amount of $60M.

  • $25M$50M

    Zevra Therapeutics's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.